CRISPR Therapeutics (CRSP) recently delivered a fourth-quarter earnings report that, on the surface, looked far from impressive. The gene-editing pioneer posted revenue of just $864,000 and a loss of $1.37 per share, both falling short of market expectations. Under normal circumstances, such results would put significant pressure on the stock.
Yet, by Friday afternoon, CRISPR shares had defied the odds, surging nearly 10%. What invisible force led investors to look past the lackluster near-term numbers and pile into the stock? The answer lies in the forward-looking guidance from its key partner, Vertex Pharmaceuticals (VRTX).
After Thursday’s closing bell, Vertex released its own quarterly results and made a notable mention of Casgevy, the groundbreaking gene-editing therapy it developed in partnership with CRISPR. Management projected that in 2026, revenue from non-cystic fibrosis products, including Casgevy, would reach “$500 million or more.” The primary driver, they stated, would be increased patient infusions channeled through Vertex’s global network of authorized treatment centers (ATCs).
This figure significantly exceeds previous market expectations. For context, Casgevy generated total revenue of just $116 million throughout all of 2025. Vertex’s guidance suggests the therapy’s sales could multiply several times over in the coming year. While Vertex did not specify exactly how much of that revenue CRISPR Therapeutics will ultimately book (the companies share profits according to an agreed-upon structure), the message to the market was loud and clear: the commercialization of Casgevy is gaining tangible momentum, and its potential is massive.
Casgevy holds the distinction of being the first CRISPR-based gene-editing therapy ever approved by the FDA, used to treat sickle cell disease and beta thalassemia. Its journey to a patient is inherently complex. The process involves harvesting a patient’s cells, editing them in a lab, and then infusing them back—a procedure that takes several months and carries a price tag of over $2 million per patient. As such, it was never expected to generate blockbuster revenue overnight like a traditional small-molecule pill.
Vertex’s optimistic outlook, however, signals that this initial “slow burn” phase is transitioning. As more treatment centers become operational and patient infusion workflows become standardized, Casgevy is evolving from a “technological miracle” into a sustainable and growing revenue stream. Analysts had already been modeling CRISPR’s 2026 revenue to approach $130 million (primarily from Casgevy royalties). Vertex’s latest projection provides powerful validation for those estimates and suggests significant upside.
Beyond the anticipated sales surge of Casgevy, CRISPR Therapeutics itself is poised for a busy year filled with pipeline milestones. The company has outlined several key objectives for 2026:
Positive data from any of these catalysts could further solidify CRISPR’s leadership in the gene-editing space and provide additional fuel for the stock throughout the year.
While the outlook is brightening, it’s crucial for investors to maintain perspective. CRISPR Therapeutics is still an unprofitable biotech company, and its stock is likely to remain highly volatile for the foreseeable future. Friday’s sharp rally is not, in itself, a reason to buy. The investment thesis hinges on the long-term potential of its robust pipeline and the gradually unfolding commercial promise of Casgevy.
As Vertex’s guidance suggests, Casgevy has only just begun to tap its potential. It currently addresses an estimated 60,000 eligible patients in the United States alone, with a vast global market beyond. As manufacturing processes are optimized and physician and patient adoption grows, this “one-time curative” therapy has the potential to become a multi-billion-dollar franchise. For investors with a long-term horizon, 2026 is shaping up to be the pivotal year when CRISPR Therapeutics begins its transition from a story of scientific promise to a story of financial performance.
